期刊文献+

卵巢癌生物标记物的研究进展 被引量:9

原文传递
导出
摘要 卵巢癌是妇科生殖系统肿瘤中最具致死性的癌症。随着社会经济的发展和生育率的降低,卵巢癌之发病率有逐年上升之势。美国国家癌症研究所估计仅2009年就有21550例新发的卵巢癌病例和14600例死亡病例,是美国第五位常见的引起女性癌症死亡的疾病。75%的卵巢癌患者就诊时已到临床晚期,而此期患者的5年生存率不足20%。由于缺少精确的早期预警症状,在疾病Ⅰ期明确诊断的病例仅占25%。大多数病例确诊时均处疾病晚期,失去治疗和生存机会。而早期确诊病例其5年生存率则高达85%~90%。与其他实体瘤经血液或淋巴系统转移途径不同,卵巢癌系经腹腔转移,症状隐匿,不易被发现。为了改善卵巢癌的生存率、降低死亡率,改善疾病早期检测技术尤为重要,目前对卵巢癌的筛查手段主要包括肿瘤标记物、超声或联合检测。
出处 《中华临床医师杂志(电子版)》 CAS 2013年第12期124-126,共3页 Chinese Journal of Clinicians(Electronic Edition)
  • 相关文献

参考文献33

  • 1Jemal A,Siegel R,Xu J. Cancer statistics,2010[J].{H}CA-A Cancer Journal for Clinicians,2010.277-300.
  • 2Merritt MA,Cramer DW. Molecular pathogenesis of endometrial and o-varian cancer[J].Cancer Biomark,2010.287-305.
  • 3Jacobs IJ,Skates SJ,MacDonald N. Screening for ovarian cancer:a pilot randomised controlled trial[J].{H}LANCET,1999.1207-1210.
  • 4Dorigo O,Berek JS. Personalizing CA125 levels for ovarian cancer screening[J].Cancer Prev Res(Phila),2011.1356-1359.
  • 5Nakae M,Iwamoto I,Fujino T. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer[J].Journal of Obstetrics and Gynaecology Re-search,2006.309-314.
  • 6Barks P,Goldgar C. Hereditary breast and ovarian cancer[J].{H}JAAPA:Official Journal of the American Academy of Physician Assistants,2012.63-65.
  • 7Wilcox CB,Baysal BE,Gallion HH. High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors[J].{H}Cancer Genetics and Cytogenetics,2005.114-122.
  • 8Van Nagell JR Jr,DePriest PD,Ueland FR. Ovarian cancer screening with annual transvaginal sonography:findings of 25000 women screened[J].{H}CANCER,2007.1887-1896.
  • 9Urban N,Drescher C. Current and future developments in screening for ovarian cancer[J].Women′s Health,2006.733-742.
  • 10Elg SA,Carson LF,Fowler JM. Ascites levels of haptoglobin in patients with ovarian cancer[J].{H}CANCER,1993.3938-3941.

同被引文献67

  • 1李山,秦雪,何卫华.血清CA125在卵巢癌诊断中的价值及文献评价[J].中华检验医学杂志,2005,28(2):209-211. 被引量:37
  • 2Moore RG, Brown AK, Miller MC, et al.The use of muhiple nover tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass[J].Gynecol Oncol, 2008, 108 ( 2 ): 402-408.
  • 3Pecorelli S.Revised F'IGO staging for carcinoma of the vulva, cervix, and endometrium[J].Int J Gynaecol Obstet, 2009,105 ( 2 ) : 103-104.
  • 4Anderson GL, Mclntosh M, Wu L, et al.Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study[J].J Nail Cancer Inst, 2010,102 ( 1 ): 26-38.
  • 5Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al.The HE4 ( WFDC2 ) protein is a biomarker for ovarian carcinoma[J].Cancer Res, 2003,63 ( 3 ) : 3695-3700.
  • 6Yurkovets Z, States S, Lomakin A, et al.Development of multimarker assay for early detetion of ovarian cancer[J].J Clin Oncol,2010,28 ( 5 ): 2159-2166.
  • 7Moor RG, Momeekin DS, Brown AK, et al.A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass[J]. Gynecol 0ncol,2009,112 ( 1 ): 40-46.
  • 8马培奇.抗肿瘤新药替吉奥钾研究进展[J].中国医药导刊,2007,9(6):499-502. 被引量:54
  • 9Merritt MA,Cramer DW.Molecular pathogenesis of endometrial and ovarian cancer[J].Cancer Biomark,2010;9(1-6):287-305.
  • 10Dorigo O,Berek JS.Personalizing CA125 levels for ovarian cancer screening[J].Cancer Prev Res(Phila),2011;4(9):1356-9.

引证文献9

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部